About
Cellbyte builds AI agents for pharmaceutical pricing, market access, and drug-launch workflows. It sells to pharmaceutical companies and differentiates through automating repetitive work on a robust data foundation, delivering answers in seconds rather than weeks to accelerate global launches.
Market
Cellbyte competes in pharmaceutical commercial intelligence and drug-launch software, spanning pricing, market access, HTA, reimbursement, regulatory intelligence, and launch planning. It positions itself as an AI-native, agentic alternative to legacy databases, manual research, and consulting-heavy workflows. Its differentiation is the combination of a globally interconnected data foundation, integrated analytics, document intelligence, and human-in-the-loop workflows that can turn previously month-long analyses into outputs delivered in minutes.
Cellbyte targets pharmaceutical companies, especially global or enterprise drug-launch organizations and their Pricing & Market Access, commercialization, regulatory, and market-access teams. Its strongest fit is with large pharma companies that need cross-market pricing, HTA, reimbursement, regulatory, and launch intelligence, as indicated by its use by leading global pharmaceutical brands including Bayer.
At a Glance
Problem
Cellbyte addresses the slow, fragmented work that follows successful clinical development: pharmaceutical teams must combine regulatory, health-technology-assessment, pricing, reimbursement, and market data to decide where and how to launch a drug. Because this information is dispersed across complex documents and legacy databases, patients can wait another one to two years for access after clinical trials succeed, while pharmaceutical companies may spend hundreds of thousands of dollars gathering and processing market data.
The clearest use case is launch sequencing and market-access planning: determining questions such as what price a new drug can achieve in the United States versus Germany, which markets to enter first, and how regulatory and reimbursement strategies should be coordinated. Cellbyte targets the manual research and anecdotal decision-making that can leave high-value launch decisions taking up to a year rather than minutes.
Product / Service
Cellbyte is a collaborative, AI-native workspace for pharmaceutical Pricing and Market Access teams. Its platform combines a globally interconnected data foundation with AI-powered analytics and agentic workflows. Drug Explorer brings together regulatory, HTA, access, and pricing data from more than 100 sources; Document Intelligence extracts insights from lengthy multilingual documents; Workflows automate repetitive processes with human-in-the-loop review; and Data Vault lets teams securely upload, benchmark, and share internal analyses.
The delivery model is enterprise software accessed through a collaborative workspace and supported by AI agents rather than a conventional database or standalone consulting engagement. Cellbyte analyzes millions of clinical, pricing, HTA, regulatory, and internal-company data points in real time, then produces insights, documents, launch sequences, and go-to-market recommendations. The intended benefit is consulting-level output with substantially less manual labor, enabling faster, more evidence-based, and lower-cost launch planning without removing human oversight from high-stakes decisions.
Market
Cellbyte competes in AI-native pharmaceutical commercial intelligence, particularly pricing and market-access analytics, regulatory intelligence, and drug-launch workflow automation. Its competitive set includes established data and analytics providers such as IQVIA, MMIT/Norstella, NAVLIN/EVERSANA, and Certara, as well as general business-intelligence tools such as Power BI and Tableau. Agentic analytics platforms such as Tellius are an adjacent competitor, although Cellbyte’s positioning is more specifically focused on global launch planning and interconnected regulatory, HTA, and pricing intelligence.
Cellbyte is commercially launched rather than pre-revenue. The company announced a $2.75 million seed round in November 2025 led by Frontline Ventures, with participation from Y Combinator, Pace Ventures, Saras Capital, and Springboard Health Angels. Within weeks of launch it reported six-figure annual recurring revenue and contracts with major pharmaceutical companies including Bayer; it also said it was expanding in the United States and Europe and had secured adoption among leading pharma brands. Its earlier company profile described coverage in 12 key markets, with additional markets being added.
Founders & Leadership
Funding History
Not publicly disclosed
Frontline Ventures
Recent News
Cellbyte announced a $2.75 million seed round led by Frontline Ventures, with participation from Y Combinator, Pace Ventures, Saras Capital, and Springboard Health Angels. The company said the funding will support international expansion, hiring, and automation of pharmaceutical drug-launch workflows.
Pace Ventures announced its participation in Cellbyte’s $2.75 million seed round, led by Frontline Ventures. The investor described Cellbyte as building AI agents to make pharmaceutical drug launches faster and more data-driven.
StartupDope reported that Munich-based Cellbyte raised $2.75 million in seed funding to help pharmaceutical companies reduce drug-launch timelines using an AI-native SaaS platform.
Cellbyte’s platform page highlighted workflow automation and collaboration features intended to help pharmaceutical teams focus on strategic tasks. The platform is positioned around pricing, market-access, regulatory, HTA, and drug-launch intelligence.
Active Roles
4Business Model
Cellbyte appears to use a demo-led B2B software model, selling AI-powered pricing and market-access intelligence to pharmaceutical companies. The company does not publicly disclose specific subscription, contract, or usage-based pricing terms in the available evidence.